Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#220 of 589

Mark Massaro

BTIG · Equity Research Analyst
ProvisionalRating since 2022No new ratings since Nov 2025

Analyst rating accuracy & track record

Mark Massaro is an equity research analyst at BTIG. Quantellect has scored 37 of their stock calls across 14 companies. Their picks beat their sector 44% of the time over the next 12 months, and their price targets were reached 51% of the time within a year.

Win % vs sector
44%
PT Hit % (12mo)
51%
Avg sector-excess
−1.9%
Scored calls
37
Tickers
14
Tier
Provisional

Track record

Quantellect has scored 37 of Mark Massaro's stock calls across 14 companies, dating back to 2022. Their rated stocks beat their own sector 44% of the time over the next 12 months. On a typical call, a Massaro pick returned −1.9% more than its sector over the following year.

Of the scored calls, 33 were bullish (Buy) and 4 were bearish (Sell). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
ZTSZoetis Inc
Buy$160.00Nov 2025−54.9%Miss
PSNLPersonalis Inc
Buy$12.00Nov 2025+74.6%Hit
SOPHSophia Genetics SA
Buy$7.00Nov 2025+43.7%Hit
XGNExagen Inc
Buy$15.00Nov 2025−69.4%Miss
NTRANatera Inc
Buy$230.00Nov 2025+26.1%Hit
CDNACareDx Inc
Buy$25.00Nov 2025+375.4%Hit
ADPTAdaptive Biotechnologies Corp
Buy$21.00Nov 2025+61.7%Hit
CSTLCastle Biosciences Inc
Buy$38.00Nov 2025−25.8%Hit
IDXXIDEXX Laboratories Inc
Buy$830.00Nov 2025−34.3%Miss
WGSGeneDx Holdings Corp.
Buy$165.00Oct 2025−74.6%Hit
NTRANatera Inc
Buy$210.00Oct 2025+86.0%Hit
PSNLPersonalis Inc
Buy$11.00Oct 2025+42.2%Hit
XGNExagen Inc
Buy$13.00Oct 2025−62.4%Miss
ADPTAdaptive Biotechnologies Corp
Buy$19.00Oct 2025+17.1%Hit
WGSGeneDx Holdings Corp.
Buy$140.00Oct 2025−71.5%Hit
CDNACareDx Inc
Buy$22.00Sep 2025+235.8%Hit
CDNACareDx Inc
Buy$22.00Sep 2025+249.4%Hit
LUCDLucid Diagnostics Inc
Buy$2.50Sep 2025−45.0%Miss
LUCDLucid Diagnostics Inc
Buy$2.50Sep 2025−49.6%Miss
DNAGinkgo Bioworks Holdings
Sell$9.00Aug 2025+70.6%Hit
ADPTAdaptive Biotechnologies Corp
Buy$9.00Dec 2024+160.0%Hit
ADPTAdaptive Biotechnologies Corp
Buy$8.00Oct 2024+185.2%Hit
DNAGinkgo Bioworks Holdings
Sell$7.00Aug 2024−63.8%Hit
DNAGinkgo Bioworks Holdings
Sell$0.20Jun 2024+15.8%Hit
BNGOBionano Genomics Inc
Buy$2.00May 2024−86.9%Miss
Prev1
Go to

Mark Massaro: analyst track record FAQ

Is Mark Massaro a good stock analyst?

Yes, by track record. Mark Massaro ranks number 220 of 589 of the analysts Quantellect scores, with an Analyst Score of 44 out of 100. Past results do not guarantee future ones.

What is Mark Massaro's win rate?

Mark Massaro's win rate is 44%. Across 37 scored calls, their rated stocks beat their sector 44% of the time over the next 12 months. On a typical call they returned −1.9% more than the sector.

What stocks and sectors does Mark Massaro cover?

Mark Massaro covers 14 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Mark Massaro's price targets accurate?

Mark Massaro's price targets are reached within 12 months 51% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Mark Massaro's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Mark Massaro rank among Wall Street analysts?

Mark Massaro ranks number 220 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.